Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
CC transcript
Director departure
Quarterly results
IMMUNE PHARMACEUTICALS INC (IMNPQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/18/2022 REVOKED Form REVOKED - Commission order revoking Exchange Act registration [Section 12(j)]:
04/13/2021 8-K Quarterly results
04/12/2021 8-K Quarterly results
08/12/2019 SC 13G Hughes Eric Olan reports a 6.2% stake in Immune Pharmaceuticals Inc.
03/08/2019 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
Docs: "EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT is entered into as of March 7, 2019, by and between Gary H. Rabin , and Immune Pharmaceuticals Inc . Company desires to engage Rabin as President and Interim Chief Executive Officerto provide certain services to Company as more particularly set forth in Exhibit A attached hereto and made a part hereof . The parties desire to set forth, in writing, the terms and conditions concerning the engagement. Accordingly, in consideration of the mutual covenants in this Agreement, and for other good and valuable consideration, it is agreed as follows: 1. Engagement and Commencement Date. Commencing on March 7, 2019 , Company hereby engages Rabin as President and Interim Chief Executive Officer, on the terms and conditions set forth in this Agreement. By ...",
"Investor Contact"
02/14/2019 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
Docs: "Notice of Default and Notice of Sale of Collateral"
02/07/2019 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
01/17/2019 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
01/08/2019 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
12/19/2018 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
12/19/2018 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of Immune Pharmaceuticals Inc"
12/06/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders"
12/06/2018 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
11/28/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights"
11/26/2018 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
11/21/2018 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/14/2018 10-Q Quarterly Report for the period ended September 30, 2018
11/08/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
10/29/2018 PRE 14A Form PRE 14A - Other preliminary proxy statements:
10/22/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
10/10/2018 8-K Quarterly results
09/18/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Securities Purchase Agreement, by and between Immune Pharmaceuticals, Inc. and Power Up Lending Group Ltd",
"Convertible Promissory Note, by and between Immune Pharmaceuticals, Inc. and Power Up Lending Group Ltd"
09/10/2018 8-K Resignation/termination of a director
08/14/2018 10-Q Quarterly Report for the period ended June 30, 2018
07/26/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018"
07/26/2018 GN Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018
07/17/2018 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
07/17/2018 DEF 14A Form DEF 14A - Other definitive proxy statements:
07/17/2018 GN Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split
06/29/2018 PRE 14A Form PRE 14A - Other preliminary proxy statements:
06/08/2018 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure...
Docs: "Investor Contact:"
06/08/2018 GN Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination
05/23/2018 GN Immune Pharmaceuticals Provides a Pipeline Update
05/14/2018 10-Q Quarterly Report for the period ended March 31, 2018
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy